A rapid mobile-based assay for determination of inflammation through quantification of alpha-1-acid glycoprotein has been developed.
As part of our Spotlight on HRMS in DMPK, we carried out a survey to gain an insight into the trends, challenges and developments associated with using HRMS for DMPK studies. We would like to thank everyone who was able to share their thoughts by taking part in the survey – you can see the results below in our infographic.
Read the Bioanalysis Zone team’s top five take away messages from the 12th EBF Open Symposium, from automation to patient-centric sampling in this conference report.
In this interview from 3DMedNet, Laura Mercolini (Alma Mater Studiorum, University of Bologna, Italy) discusses how the latest 3D printing techniques and technology are enhancing bioanalytical research: from sampling to sample handling, pretreatment and instrumental analysis.
In this interview we find out where Jing Tu (the 2018 BRSA winner) is now and key developments that have evolved over the last year.
In this installment of Robert MacNeill’s (Covance) column, Robert discusses the potential disparity in results when using a given method for extracted analytical batches versus in solution, the different challenges involved with solutions and extracts and the necessity to fully consider the relevant chemistry from the earliest stages of method development.
In this feature, we explore the key qualities to look for to ensure success when outsourcing immunogenicity assay development and testing. We also explore the methods for – and challenges involved with – T-cell immunity monitoring and assay development.
High-resolution mass spectrometry: an essential tool for DMPK studies of novel peptide-based modalities
In this editorial Simone Esposito (IRBM, Italy) explores how HRMS has become a well established alternative to multiple reaction monitoring for DMPK profiling and discusses the use of HRMS for DMPK studies of nove peptide-based modalities.
In this interview Joel Mathews (Ionis Pharmaceuticals Inc., CA, USA) discusses his role in the development of biomarker, PK and immunogenicity assays in the development of protein therapeutics. He explains his interest in the field and explores the use of LBA for biomarker validation
A collection of helpful answers to the most frequently asked questions concerning the use of high-resolution mass spectrometry (HRMS) in drug metabolism and pharmacokinetics (DMPK).